FUSION SYSTEM
Dead / Abandoned — Abandoned — no statement of use filed (as of 09 Oct 2025)
What this means for you
This application is over — abandoned 09 Oct 2025. The name may be available, but check before relying on it — rights can also come from actual use, not only from the register.
Record
- Serial number
- 90478027
- Mark type
- Stylized text
- Filed
- 20 Jan 2021
- Published for opposition
- 21 Dec 2021
- Abandoned
- 09 Oct 2025
- Attorney of record
- Philip R. Zender
Goods and services
- Class 005 — Pharmaceuticals: Adjuvants for medical purposes; Anti-cancer preparations; Anti-sarcoma preparations; Cellular function activating agents for medical purposes; Chemical preparations for pharmaceutical or medical purposes, namely, for cancer and metabolic diseases; Chemotherapeutics; Cytostatics for pharmaceutical purposes; Diagnostic preparations for medical purposes; Medical preparations for the treatment of cancer and metabolic diseases; Medicinal infusions for treating cancer and metabolic diseases; Medicinal preparations for the treatment of infectious diseases and for use in oncology; Medicinal preparations for cancer and metabolic diseases; Pharmaceutical preparations and substances for the treatment of damaged skin and tissue; Pharmaceutical preparations and substances for the treatment of infectious diseases, blood disorders, pain, inflammation, sepsis, alopecia, obesity and cognitive disorders; Pharmaceutical preparations and substances for the treatment of viral, metabolic, endocrine, musculoskeletal, cardiovascular, cardiopulmonary, genitourinary, sexual dysfunction, oncological, hepatological, ophthalmic, respiratory, neurological, gastrointestinal, hormonal, dermatological, psychiatric and immune system related diseases and disorders; Pharmaceutical preparations for the prevention of cancer and metabolic diseases; Pharmaceutical preparations for the treatment and prevention of cancer and metabolic diseases; Pharmaceutical preparations for the treatment of immune system related diseases and disorders; Pharmaceutical preparations for the treatment of cancer and metabolic diseases; Pharmaceutical preparations for treating chemical imbalances; Pharmaceutical preparations for use in chemotherapy; Pharmaceutical preparations for cancer and metabolic diseases; Pharmaceutical preparations, namely, a drug delivery system comprising polymer-based oral tablets for the continuous release of a wide variety of therapeutic agents; Pharmaceutical preparations, namely, elixirs for the treatment of cancer and metabolic diseases; Pharmaceutical products for the prevention and treatment of cancer; Pharmaceutical products for the treatment of cancer; Pharmaceutical products for the treatment of viral and infectious diseases, for the treatment of cancer; Therapeutic pharmaceutical for the treatment of cancer and metabolic diseases; Tumor suppressing agents
- Class 042 — Scientific and technological services: Biotechnology research; Development of new technology for others in the field of cancer and metabolic diseases; Development of pharmaceutical preparations and medicines; Medical and scientific research in the field of cancer treatment and diagnosis; Medical research services; Pharmaceutical drug development services; Pharmaceutical products development; Pharmaceutical research and development; Pharmaceutical research services; Providing information on the subject of scientific research in the field of biochemistry and biotechnology; Providing medical and scientific research information in the field of pharmaceuticals and clinical trials; Providing medical and scientific research information in the fields of pharmaceuticals and genetics; Providing medical research and scientific research information in the field of oncology via the Internet; Providing medical testing services and information in the field of cancer research and disease classification; Research and development in the pharmaceutical and biotechnology fields; Research and development of pharmaceuticals for the treatment of age-related diseases and cancer; Research and development of vaccines and medicines; Scientific research for medical purposes in the area of cancerous diseases; Scientific research for medical purposes in the field of cancer and metabolic diseases; Testing of pharmaceuticals
- Class 044 — Medical, beauty and agricultural services: Providing a web site featuring medical information; Providing a website featuring information in the field of the diagnosis and treatment of cancer and metabolic diseases
Owner
- Biomea Fusion, Inc., Redwood City, CA, US
- Biomea Fusion, Inc., Redwood City, CA, US
Prosecution history
- 09 Oct 2025 — ABANDONMENT NOTICE E-MAILED - NO USE STATEMENT FILED
- 09 Oct 2025 — ABANDONMENT - NO USE STATEMENT FILED
- 13 Aug 2024 — NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
- 13 Aug 2024 — SOU EXTENSION 5 GRANTED
- 13 Aug 2024 — SOU EXTENSION 5 FILED
- 13 Aug 2024 — SOU TEAS EXTENSION RECEIVED
- 09 Feb 2024 — NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
- 08 Feb 2024 — SOU EXTENSION 4 GRANTED
- 08 Feb 2024 — SOU EXTENSION 4 FILED
- 08 Feb 2024 — SOU TEAS EXTENSION RECEIVED
- 15 Aug 2023 — NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
- 11 Aug 2023 — SOU EXTENSION 3 GRANTED
- 11 Aug 2023 — SOU EXTENSION 3 FILED
- 11 Aug 2023 — SOU TEAS EXTENSION RECEIVED
- 20 Dec 2022 — NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED